RKV — Rakovina Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- CA$3.30m
- CA$5.59m
Annual balance sheet for Rakovina Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 2.81 | 0.897 | 0.436 | 1.31 | 0.299 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.074 | 0.015 | 0.02 | 0.081 | 0.056 |
| Prepaid Expenses | |||||
| Total Current Assets | 3.07 | 1.07 | 0.633 | 2.26 | 0.801 |
| Net Intangible Assets | |||||
| Total Assets | 8.66 | 6.12 | 5.15 | 6.24 | 4.24 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.114 | 0.107 | 0.155 | 1.94 | 2.95 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.114 | 0.107 | 1.49 | 1.94 | 4.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 8.54 | 6.01 | 3.66 | 4.3 | 0.14 |
| Total Liabilities & Shareholders' Equity | 8.66 | 6.12 | 5.15 | 6.24 | 4.24 |
| Total Common Shares Outstanding |